Ledelsen gleder seg til kommende emisjonen som også skal dekke deres bonusutbetalinger. Hver av dem skal få opptil en vis % av grunnlønnen som bonus, på toppen av dette kommer sikkert opsjoner. Dette er bare galskap, på toppen av millionlønninger og opsjoner skal også betales bonuser. TRVX tjener 0 kroner, har en gjeld på 60-65 mil og overlever av emisjoner.

Side 8:
Øystein Soug (Chief Executive Officer) 35% of base salary
Magnus Jäderberg (Chief Medical Officer) 30% of base salary
Erik Digman Wiklund (Chief Business Officer) 30% of base salary
Torbjørn Furuseth (Chief Financial Officer) 30% of base salary
Anne-Kirsti Aksnes (VP Clinical Development) 20% of base salary
Berit Iversen (VP, Head of CMC 20% of base salary

I 2018 tjente de (side 58):
Magnus Jäderberg, Chief Medical Officer: 3.150 millioner
Øystein Soug, Chief Executive Officer 2.575 millioner
Berit Iversen, VP CMC 1.275 millioner
Anne Kirsti Aksnes, VP Clinical Development 1.435 millioner
Torbjørn Furuseth, Chief Financial Officer Quality Assurance 1.850 millioner
Erik Digman Wiklund, Chief Business 1.700 millioner

Side 56:
In 2018 Targovax implemented a bonus system covering all employees who are not part of the management team. The criteria are the same as for the management team; based on the achievement of the corporate objectives as well as individual objectives.

Side 83
The Group has received three R&D loans from Business Finland, for the commercialization of ONCOS-102, under loan agreements dated September 2010, January 2012 and December 2013, respectively, in the total outstanding amount of EUR 6.3 million as of 31 December 2018 (EUR 6 .3 million as of 31 December 2017). An additional loan approval of EUR 0.3 million was granted to one of the existing Business Finland loans during 2017, hence a grant element of EUR 0.09 million (NOK 0.9 million) was recognized in 2017. EUR 0.9 million of the total debt EUR 6.3 million is short-term as per 31 December 2018.

https://www.targovax.com/en/wp-content/uploads/sites/2/2019/04/1904-trvx-annual-report-v4.pdf